Stock Track | Arrowhead Pharmaceuticals Soars 5.49% Intraday on Morgan Stanley Price Target Hike and Bullish Analyst Sentiment

Stock Track
11/26

Arrowhead Pharmaceuticals (ARWR) saw its stock surge 5.49% during intraday trading on Wednesday, reflecting strong investor confidence in the company's growth trajectory.

The rally was fueled by Morgan Stanley raising its price target on Arrowhead to $48 from $45, while maintaining an Equal Weight rating. Additionally, TD Cowen reiterated its Buy rating, citing promising developments in the Redemplo launch and strategic advancements in obesity treatments. These analyst actions underscore the market's optimism about Arrowhead's future performance.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10